Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.64 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL27577950 | 1.00 | TSHR (0.64) | TSHRTP53EGLN1EGLN3BLM | |
| Fumaric Acid SCHEMBL4770513 | 1.00 | TSHR (0.64) | TSHRTP53EGLN1EGLN3BLM | |
| Fumaric Acid SCHEMBL4770527 | 1.00 | TSHR (0.64) | TSHRTP53EGLN1EGLN3BLM | |
| Maleic Acid SCHEMBL8050273 | 1.00 | TSHR (0.64) | TSHRTP53EGLN1EGLN3BLM | |
| Fumaric Acid SCHEMBL15689651 | 0.85 | TSHR (0.75) | TSHRTP53EGLN1EGLN3BLM | |
| Fumaric Acid SCHEMBL365675 | 0.85 | TSHR (0.75) | TSHRTP53EGLN1EGLN3BLM | |
| Maleic Acid SCHEMBL15239556 | 0.85 | TSHR (0.75) | TSHRTP53EGLN1EGLN3BLM | |
| Fumaric Acid SCHEMBL5874229 | 0.85 | TSHR (0.75) | TSHRTP53EGLN1EGLN3BLM | |
| Fumaric Acid SCHEMBL1062045 | 0.85 | TSHR (0.75) | TSHRTP53EGLN1EGLN3BLM | |
| Fumaric Acid SCHEMBL365677 | 0.85 | TSHR (0.75) | TSHRTP53EGLN1EGLN3BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452983-A1 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-30 | — | — | EP | claimed |
| CN-118401526-A | Solid forms of TYK2 inhibitors, methods of preparation and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | claimed |
| WO-2023116822-A1 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-29 | — | — | WO | claimed |
| CN-1726208-A | Complexes of E-2-methoxy-N-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use | PFIZER PROD INC (US) | 2006-01-25 | — | — | CN | claimed |
| EP-4452983-A1 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-30 | — | — | EP | disclosed |
| CN-118401526-A | Solid forms of TYK2 inhibitors, methods of preparation and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023116822-A1 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-29 | — | — | WO | disclosed |
| CN-110062755-A | Maleate salt of the free base of N- [5- (aminosulfonyl) -4-methyl-1, 3-thiazol-2-yl ] -N-methyl-2- [4- (2-pyridinyl) -phenyl ] acetamide, pharmaceutical preparation thereof, method for the production thereof and use thereof for the treatment of herpes viruses | 艾库里斯抗感染治疗有限公司 | 2019-07-26 | — | — | CN | disclosed |
| CN-102234287-B | Nitro glyoxaline compound, Preparation Method And The Use | SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2015-08-05 | — | — | CN | disclosed |
| CN-103396399-B | Nitrogenated aromatic 6-membered ring derivative, and pharmaceutical agent comprising same | DAIICHI SANKYO CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-103501777-A | Pharmaceutically acceptable cocrystal of N- [2- (7-methoxy-1-naphthyl) ethyl ] acetamide and preparation method thereof | ZENTIVA KS | 2014-01-08 | — | — | CN | disclosed |
| CN-102307869-A | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO LTD | 2012-01-04 | — | — | CN | disclosed |
| CN-101781293-A | Antibacterial compound, preparation method and application thereof | BENXI RUISHENG PHARMACEUTICAL | 2010-07-21 | — | — | CN | disclosed |
| CN-101472892-A | Organic compounds | NOVARTIS AG (CH) | 2009-07-01 | — | — | CN | disclosed |
| CN-101437811-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| US-20040029865-A1 | Sleep disorders; eating disorders; schizophrenia disorders; anxiolytic agents | PHARMACIA & UPJOHN COMPANY | 2004-02-12 | — | — | US | disclosed |
| WO-2003099797-A1 | SALTS OF BIS-ARYLSULFONES FOR THE TREATMENT OF CNS DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| CN-1069490-A | Urea derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1993-03-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029865-A1 | Sleep disorders; eating disorders; schizophrenia disorders; anxiolytic agents | HCRTR2, HCRTR1, CNR1 | TSHR 358/4885TP53 4885/4885EGLN1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.